Arunachal Pradesh Headlines

Neurological Disorder Drugs Market: Know Applications Supporting Impressive Growth | Novartis, Bayer, Amgen

 Breaking News
  • No posts were found

Neurological Disorder Drugs Market: Know Applications Supporting Impressive Growth | Novartis, Bayer, Amgen

February 25
03:35 2020
Neurological Disorder Drugs Market: Know Applications Supporting Impressive Growth | Novartis, Bayer, Amgen

Neurological Disorder Drugs Market
The Global Neurological Disorder Drugs Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2019-2025). The assessment provides a 360° view and insights, outlining the key outcomes of the industry. These insights help the business decision-makers to formulate better business plans and make informed decisions for improved profitability.

A new independent 150 page research with title ‘Global Neurological Disorder Drugs Market Insights by Application, Product Type, Competitive Landscape & Regional Forecast 2025’  guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, Europe & Asia and important players/vendors such as Novartis International AG (Switzerland), Johnson and Johnson (United States), GlaxoSmithKline (United Kingdom), Pfizer (United States), Amgen (United States), UCB (Belgium), Merck & Co (United States), Bayer (Germany), AstraZeneca and Boehringer Ingelheim (Germany) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Neurocrine Biosciences (United States), Biogen (United States), Eli Lilly and Company (United States), Ionis Pharmaceuticals (United States), Adamas Pharmaceuticals (United States), BioMarin Pharmaceutical (United States), Otsuka America Pharmaceutical (United States) and AstraZeneca (United States). With n-number of tables and figures examining the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2025.

Request a sample report @ https://www.htfmarketreport.com/sample-report/2505906-global-neurological-disorder-drugs-market-10

#Summary:
Neurological Disorder Drugs Market Scope

A neurological disorder is any medical condition that affects the nervous system which includes the brain, spinal cord, and other nerves. Problems with the structure or function of any part of the nervous system can lead to a neurological disorder. According to the World health organization, more than 6 million people die because of stroke each year; over 80% of these deaths take place in low- and middle-income countries. More than 50 million people have epilepsy worldwide. It is estimated that there are globally 47.5 million people with dementia with 7.7 million new cases every year – Alzheimer’s disease is the most common cause of dementia and may contribute to 60–70% of cases. The prevalence of migraine is more than 10% worldwide

The market study is being classified by Type (Antipsychotic, Hypnotic & Sedative, Analgesics, Anticoagulants and Others), by Application (Hospital, Clinic and Home) and major geographies with country level break-up.

The Neurological Disorder Drugs market is highly fragmented with the presence of many players worldwide. Some of the leading players are adopting some organic and inorganic strategies such as a merger, acquisition, expansion, new product launches, among others in order to gain leading share within the market. There are scopes for expansion with the surge in new improved products being launched owing to technological advancements Research Analyst at AMA predicts that United States and European Players will contribute to the maximum growth of Global Neurological Disorder Drugs market throughout the predicted period.

Novartis International AG (Switzerland), Johnson and Johnson (United States), GlaxoSmithKline (United Kingdom), Pfizer (United States), Amgen (United States), UCB (Belgium), Merck & Co (United States), Bayer (Germany), AstraZeneca and Boehringer Ingelheim (Germany) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Neurocrine Biosciences (United States), Biogen (United States), Eli Lilly and Company (United States), Ionis Pharmaceuticals (United States), Adamas Pharmaceuticals (United States), BioMarin Pharmaceutical (United States), Otsuka America Pharmaceutical (United States) and AstraZeneca (United States).

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/2505906-global-neurological-disorder-drugs-market-10

Segmentation Overview:
HTF MI has segmented the market of Global Neurological Disorder Drugs market by Type, Application and Region.

On the basis of geography, the market of Neurological Disorder Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies:
In December 2019, The U.S. Food and Drug Administration approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults and In November 2019, Philips launched Philips Intellispace Cognition, the digital, cloud-based assessment tool that takes established neuropsychological tests and enables their administration by a medical assistant via a tablet in an office setting
In June 2019, Pfizer acquired Array BioPharma expanding its operations in the United States

Market Trend:
The rise in usage of Artificial intelligence and Machine Learning in the current care of neurological disorders.

Market Drivers:
Presence of large geriatric population suffering from neurological problems like Alzheimer’s disease and Parkinson’s disease.
Increased awareness about available preventive drugs for diseases like dementia, epilepsy, multiple sclerosis and migraine, owing to advancements in drug technology.

Opportunities:
Breakthrough research in neurological disorders can provide pharmaceuticals companies with increased opportunities for their market growth.
Growing neurological disorders worldwide can provide emerging prospects for drug retailers.

Restraints:
Stringent government regulations for approval of drugs.

Challenges:
Research and development initiatives for drug formulations are expensive.
Provision of affordable drugs inconsideration with developing and underdeveloped countries.

Place a Purchase Order for this Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=2505906

Key Target Audience
Pharmaceutical Companies, Pharmacy Chains/Drug Stores, Drug Suppliers/Traders, Drug Exporters/Importers, Investors, Regulatory and Government Bodies, Upstream Vendors, Downstream Vendors and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Strategic Points Covered in Table of Content of Global Neurological Disorder Drugs Market Insights by Application, Product Type, Competitive Landscape & Regional Forecast 2025 Market:
Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Global Neurological Disorder Drugs Market Insights by Application, Product Type, Competitive Landscape & Regional Forecast 2025market. (Introduction, Scope of the Report)Chapter 2: Exclusive Summary

….Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/2505906-global-neurological-disorder-drugs-market-10

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Media Contact
Company Name: HTF Market Intelligence Consulting Private Limited
Contact Person: Craig Francis
Email: Send Email
Phone: 2063171218
Address:Unit No. 429, Parsonage Road
City: Edison
State: New Jersey
Country: United States
Website: https://www.htfmarketreport.com/reports/2505906-global-neurological-disorder-drugs-market-10

Related Articles